Advertisement

Practical Applications of the Molecular Genetics of Colorectal Cancer

  • James Church
  • Graham Casey
Chapter
Part of the Developments in Oncology book series (DION, volume 82)

Abstract

Predicting the future in medicine is a difficult task, especially in the field of molecular genetics. The rate of progress over the last 8 years has been so great that were it to continue, developments might occur that today are unthinkable. Many of the recent advances have not yet become routine clinical tools, but the next few years will likely see this happen. The effects of future developments and the transfer of current technology from the laboratory to the bedside will have profound effects on all aspects of care of patients with colorectal neoplasia. In this chapter some of the potential effects are discussed.

Keywords

Colorectal Cancer Familial Adenomatous Polyposis Mismatch Repair Colorectal Neoplasia Virtual Colonoscopy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93: 858–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Ahlquist DA, Skoletsky JE, Boynton KA et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219–27.PubMedCrossRefGoogle Scholar
  3. 3.
    Laken SJ, Peterson GM, Gruber SB et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997; 17: 79–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Lamlum H, Al Tassan N, Jaeger E, et al. Germline APC variants in patients with multiple colorectal adenomas, with evidence for the particular importance of E1317Q. Hum Mol Genet 2000; 9: 2215–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Houlston RS. Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology. 2001; 121: 282–301.PubMedCrossRefGoogle Scholar
  6. 6.
    Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299: 1753–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Dachman AH. Yoshida H. Virtual colonoscopy: past, present, and future. Radiol Clin N Am. 2003; 4: 377–93.CrossRefGoogle Scholar
  8. 8.
    Fletcher JG. Future directions in CT colonography. Abd Imag 2002; 27: 301–8.CrossRefGoogle Scholar
  9. 9.
    Gryfe R, Kim H, Hsieh ETK et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Offit K. Genetic prognostic markers for colorectal cancer. N Engl J Med 2000; 342: 124–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Caplin S, Cerottini JP, Bosman FT et al. For patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 1998; 83: 666–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Kern SE, Fearon ER, Tersmette KWF, et al. Allelic loss in colorectal carcinoma. J Am Med Assoc 1989; 261:3099–103.CrossRefGoogle Scholar
  13. 13.
    Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102; 1136–41.PubMedGoogle Scholar
  14. 14.
    Martinez-Lopez E, Abad A, Font A, et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998; 114: 1180–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Lanza G, Matteuzzi M, Gafa R, et al. Chromosome 18q allelic loss and prognosis in stage II and IIIcolon cancer. Int J Cancer 1998; 79: 390–5PubMedCrossRefGoogle Scholar
  16. 16.
    Peterson S, Thames HD, Nieder C, et al. The results of colorectal cancer treatment by p53 status. Treatment-specific overview. Dis Colon Rectum 2001; 44: 322–34.CrossRefGoogle Scholar
  17. 17.
    Pricolo VE, Finkelstein SD, Hansen K, et al. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg 1997; 132: 371–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Shibata D, Reale MA, Lavin P et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335; 1727–32.PubMedCrossRefGoogle Scholar
  19. 19.
    Bleeker WA, Hayes VM, Karrenbeld A, et al. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum 2001; 44: 358–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Bell SM, Scott N, Cross D, et al. Prognostic value of p53 over expression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993; 104; 57–64.PubMedGoogle Scholar
  21. 21.
    Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299–304.PubMedGoogle Scholar
  22. 22.
    Andreyev J, Cunningham D. Markers, markers everywhere. Prognosis in colorectal cancer-time for a new approach. J Clin Oncol 2001; 19: 286–8.PubMedGoogle Scholar
  23. 23.
    Bright-Thomas RM, Agrawal A, Hargest R. Preclinical studies of gene transfer for the treatment of desmoid disease in familial adenomatous polyposis. Br J Surg 2002; 89: 1563–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Lew JI, Guo Y, Kim RK, Vargish L, Michelassi F, Arenas RB. Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive. J Gastrointest Surg 2002; 6: 563–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Kwong KY, Zou Y, Day CP, Hung MC. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. Oncogene 2002; 21: 8340–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Mayer-Kuckuk P, Banerjee D, Kemeny N, Fong Y, Bertino JR. Molecular therapies for colorectal cancer metastatic to the liver. Mol Ther 2002; 5(5 Pt 1):492–500.PubMedCrossRefGoogle Scholar
  27. 27.
    Palmer DH, Chen MJ, Kerr DJ. Gene therapy for colorectal cancer. Br Med Bull 2002;64:201–25.PubMedCrossRefGoogle Scholar
  28. 28.
    Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998; 58: 5473–7.PubMedGoogle Scholar
  30. 30.
    Ruschoff J, Wallinger S, Dietmaier W, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Nat Acad Sci USA. 1998; 95: 11301–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Winde G, Schmid KW, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 1995;38:813–830.PubMedCrossRefGoogle Scholar
  32. 32.
    Aebi S, Kudi-Hardar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087–90.PubMedGoogle Scholar
  33. 33.
    Caruthers JM, Chauhan DP, Fink D, et al. Mismatch repair deficiency and in vivo response to 5-fluorouracil. Gastroenterology 1999; 117: 123–31.CrossRefGoogle Scholar
  34. 34.
    Caruthers JM, Hawn MT, Chauhan DP, et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N’-nitro-N-nitrosoguanidine. J Clin Invest 1996; 98: 199–206.CrossRefGoogle Scholar
  35. 35.
    Thompson JA, Wiesner GL, Sellers TA, et al. Genetic services for familial cancer patients: a survey of National Cancer Institute cancer centers. J Nat Cancer Inst 1995; 87: 1446–1455.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • James Church
    • 1
  • Graham Casey
    • 2
  1. 1.Department ofColorectal SurgeryThe Cleveland Clinic FoundationClevelandUSA
  2. 2.Lerner Research InstituteThe Cleveland Clinic FoundationCleveland

Personalised recommendations